About Accelovance
Accelovance is a Healthcare company based in Rockville (United States) founded in 2005, and was acquired by Linical in March 2018. CRO specializing in Phase I-IV programs of Vaccines, Early Phase Oncology, and General medicine. Accelovance has raised $4 million across 3 funding rounds from investors including European Union and Linical. Accelovance has completed 2 acquisitions, including Altairclinical and Ntouch Research. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its competitors include Celgene, Syneos Health and Medelis WCCT Global; 2 of its 3 listed competitors have raised funding.
Company details
Accelovance is a full service CRO offering a wide range of services for Phase I to IV trials. Their offerings are protocol management, project and data management, clinical trial monitoring, biostatistics, patient recruitment, regulatory affairs, pharmacovilgilance, medical writing etc., Its Clinical Call Center helps them in managing patient recruitment, retention, compliance, surveillance or safety. Accelovances Elite Monitoring service offers flexible staffing solutions based on customer requirements. Their offerings are catered to oncology, vaccines and general medicine which includes cardiovascular, dermatology, nutrition, urology, and womens health. It has offices in North America, Europe and China and partnerships in India, Asia Pacific and South America.
- Headquarters Rockville, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website accelovance.com
- Social LinkedIn X Facebook
- Acquired by Linical (Mar 2018)
- Total Equity Funding$4M (USD)
in 3 rounds
- Latest Funding Round$545.04K (USD), Grant
Sep 2015
- InvestorsEuropean Union
& 1 more
- Investments & AcquisitionsAltairclinical
& 1 more
- Acquired byLinical
(Mar 2018)
Funding Insights of Accelovance
Accelovance has successfully raised a total of $4M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $545.04 thousand completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 3
- Last Round Grant — $545,040
- First Round $4M
(Dec 2005)
- Investors Count 1
All 3 funding rounds of Accelovance with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2015 | $545,040 | Grant | – | – | |
| May 2015 | $1.13M | Grant | – | – | |
| Dec 2005 | $4M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Accelovance
Accelovance has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Linical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Full-service CRO operations are conducted across more than 20 countries. | 2005 | linical.com | Osaka, Japan |
Investor details for Accelovance
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Accelovance
Accelovance has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Altairclinical and Ntouch Research.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Clinical services are provided through Altair Clinical's platform. | altairclinical.com | 0 | Feb 2015 | •••• | ||
Full service CRO | ntouchresearch.com | Raleigh, United States | 1997 | Feb 2005 | •••• |
Complete acquisition details for Accelovance
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Accelovance
6 dated milestones of Accelovance across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Accelovance is founded.
- Acquisition Acquires Ntouch Research.
- Funding First funding round of $4.0M.
- Acquisition Acquires Altairclinical.
- Funding Latest funding round, Grant, of $545K.
- Exit Acquired by Linical.
Competitors of Accelovance
Accelovance has 3 listed competitors in our database, 2 of them funded. They include Celgene, Syneos Health and Medelis WCCT Global.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| syneoshealth.com | 1984 | Raleigh, United States | 29,395 | CRO clinical development services are provided by Syneos Health. | ||
| wcct.com | 1998 | Cypress, United States | $17M | 229 | Full-service CRO expertise in influenza and oncology research is offered. |
Detailed competitors of Accelovance
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Accelovance
Websites that share an audience with Accelovance (accelovance.com).
Websites whose visitors overlap most with Accelovance. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| proteogenex.com | 100% | 2.5K | #7,820,245 | View details | |
| georgeclinical.com | 98% | View details | |||
synergosinc.com | synergosinc.com | 98% | – | ||
| dominionfertility.com | 65% | View details | |||
factory-cro.com | factory-cro.com | 62% | – |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Accelovance (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Accelovance
Complete news archive for Accelovance
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Accelovance
Accelovance was founded in 2005.
Accelovance is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Accelovance is a funded company, having raised a total of $4M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Dec 2005.
Accelovance is a full service CRO offering a wide range of services for Phase I to IV trials. Their offerings are protocol management, project and data management, clinical trial monitoring, biostatistics, patient recruitment, regulatory affairs, pharmacovilgilance, medical writing etc., Its Clinical Call Center helps them in managing patient recruitment, retention, compliance, surveillance or safety. Accelovances Elite Monitoring service offers flexible staffing solutions based on customer requirements. Their offerings are catered to oncology, vaccines and general medicine which includes cardiovascular, dermatology, nutrition, urology, and womens health. It has offices in North America, Europe and China and partnerships in India, Asia Pacific and South America.
Accelovance's top competitors include Syneos Health, Medelis WCCT Global and Celgene.
Accelovance has made 2 acquisitions, including Altairclinical, and Ntouch Research.
Accelovance has 2 investors. Key investors include European Union, and Linical.
Yes. Accelovance was acquired by Linical in March 2018.